Considering that AST has no fusion labeling and no 510(k) it views itself as the first to market with this device in the United States. Hopefully the investors at Oxford, Bioventures, Interwest, DeNovo, Growth Capital and MB Ventures have all learned a lesson about rolling the dice on a technology that had greater odds than Seabiscuit. Just like Seabiscuit, the Stabilimaxx is tired and sore. If anyone is interested in buying this technology and continuing to develop it, it will take a Tom Smith like trainer to reign in the lack of continuity that this company has experienced. From the beginning, this company was doomed. Tom Woods as CEO, the legendary JP Timms as its VP of R&D. Craig Corrance was hired to do whatever it is that he does to get this to the market. Unfortunately, all other so called dynamic stabilization devices are caught under the FDA's 522 order, which gives the FDA the authority to require a manufacturer to conduct post-market surveillance of a Class II or Class III device that meets their criteria.
In addition to all of these challenges, AST has had to deal with a few failures which originally surfaced during the 2008 NASS meeting in Toronto. Maybe the VC's need to learn to talk to some of the real people in the trenches in this industry. The financial analysts and soothsayers that have permeated this industry have done more harm than good. As far back as 2006, there were engineers that had looked at this product that said, "Panjabi or No Panjabi, this product is never going to get to the market." Looks like Gerbsman and Partners is looking for someone to buy the scalp of AST. Is the Dynamic Stabilization Market dead in the water? TSB wants to know what our readers think?